Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700735 · ClinicalTrials.gov registry record
Cross Therapy Registry - Edema - US
A clinical trial, sponsored by Firstkind.
- Completed
- Registry status
- 83
- Enrollment target
NCT04700735: Completed study, sponsored by Firstkind.
NCT04700735 is a clinical trial that has completed, run by Firstkind. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700735 has completed, sponsored by Firstkind.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
Study Summary
The geko™ Cross Therapy Registry - Edema (gekoTM CTR - Edema) study will prospectively and systematically collect clinical data on all device variants used in standard care pathways for edema management allowing for the monitoring of patient outcomes during a follow-up period of up to twelve months.
Primary Outcome
Safety: determine frequency of adverse events (AEs) and serious AEs (SAEs) whether device related or not and compare rate to historic and published data i.e. gekoTM vs standard of care (SC).
Interventions
- DEVICE geko Neuromuscular Electro Stimulator (NMES)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2023-11-09 |
What the finished NCT04700735 record still lists
NCT04700735 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which geko Neuromuscular Electro Stimulator (NMES) is the first listed.
NCT04700735 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04700735 about?
NCT04700735 is a clinical study titled "Cross Therapy Registry - Edema - US". The geko™ Cross Therapy Registry - Edema (gekoTM CTR - Edema) study will prospectively and systematically collect clinical data on all device variants used in standard care pathways for edema management allowing for the monitoring of patient outcomes during a follow-up period of up to twelve months.
What is the current status of trial NCT04700735?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2021-06-22. Estimated completion is 2023-11-09.
What interventions are being tested in trial NCT04700735?
The interventions under investigation include: geko Neuromuscular Electro Stimulator (NMES) (DEVICE).
Who is sponsoring clinical trial NCT04700735?
This trial is sponsored by Firstkind, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI